Expansion momentum CBSET is aggressively expanding its preclinical facilities with a 110,000-square-foot lab in Waltham and a new presence in New York, signaling a clear demand for larger-scale translational capabilities and potential partner opportunities to co-develop tools and models.

Foreign biotech gateway The company is positioning itself as a US gateway for international biotechs, offering an entry point for foreign firms to access U.S. preclinical services, regulatory pathways, and market access, creating multiple collaboration and outsourcing opportunities.

Strategic funding Recent growth funding from Arlington Capital Partners and the corresponding facility build-out indicate strong financial backing and an appetite for scale, suggesting readiness for multi-year partnerships, large programs, and embedded collaboration engagements.

Integrated capabilities CBSET’s focus on minimally invasive techniques across cardiology, endoscopy, surgery, drug and device delivery, safety, and diagnostic imaging provides a broad services stack that can complement sponsor programs from early discovery through preclinical validation, enabling cross-domain collaborations.

Technology enabled A tech-enabled operation employing modern tools (WordPress, Salesforce, M365, Google Tag Manager, etc.) supports scalable project management, data integration, and client engagement, presenting opportunities to propose digital workflow improvements, data analytics collaborations, or platform-based partnerships.